Abrocitinib and upadacitinib seem to be slightly better than dupilumab for the treatment of AD, according to a study published in JAMA Dermatology. Aaron M. Drucker, MD, from the University of Toronto, and colleagues compared reported measures of efficacy and assessment of safety in clinical trials of systemic AD treatments as part of a living systematic review and meta-analysis. Twenty-one new studies were added since October 2019, for a total of 60 studies, involving 16,579 patients. The researchers found that in terms of the Eczema Area and Severity Index (EASI), up to 16 weeks of treatment in adults with abrocitinib 200 mg daily and upadacitinib 30 mg daily were associated with slightly greater reductions than dupilumab 600 mg then 300 mg every 2 weeks (mean differences, 2.2 and 2.7, respectively). Compared with dupilumab, there were slightly smaller reductions seen in EASI with abrocitinib 100 mg daily, baricitinib 4 mg daily, baricitinib 2 mg daily, and tralokinumab, 600 mg then 300 mg every 2 weeks (mean differences, −2.1, −3.2, −5.2, and −3.5, respectively). Little or no difference was seen between upadacitinib 15 mg daily and dupilumab.
